Novo Nordisk slams Danish Medicines Council's methodology: Has flaws and shortcomings
Novo Nordisk’s Danish management has sent a strongly worded letter criticizing the Danish Medicines Council’s use of meta-analysis following the release of Denmark’s first treatment guideline for type 2 diabetes.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
A few weeks ago, Novo Nordisk expressed its discontent in a letter sent to the Danish Medicines Council over its treatment guidelines for type 2 diabetes.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.